Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ptc Therapeutics (PTCT) Net Income: 2012-2025

Historic Net Income for Ptc Therapeutics (PTCT) over the last 14 years, with Sep 2025 value amounting to $15.9 million.

  • Ptc Therapeutics' Net Income rose 114.90% to $15.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $489.4 million, marking a year-over-year increase of 190.32%. This contributed to the annual value of -$625.6 million for FY2024, which is 12.53% up from last year.
  • According to the latest figures from Q3 2025, Ptc Therapeutics' Net Income is $15.9 million, which was up 124.51% from -$64.8 million recorded in Q2 2025.
  • Ptc Therapeutics' 5-year Net Income high stood at $866.6 million for Q1 2025, and its period low was -$328.2 million during Q4 2024.
  • In the last 3 years, Ptc Therapeutics' Net Income had a median value of -$106.7 million in 2024 and averaged -$47.6 million.
  • Its Net Income has fluctuated over the past 5 years, first crashed by 91.74% in 2021, then surged by 1,046.28% in 2025.
  • Quarterly analysis of 5 years shows Ptc Therapeutics' Net Income stood at -$143.3 million in 2021, then dropped by 21.82% to -$174.5 million in 2022, then tumbled by 40.05% to -$244.4 million in 2023, then slumped by 34.27% to -$328.2 million in 2024, then surged by 114.90% to $15.9 million in 2025.
  • Its last three reported values are $15.9 million in Q3 2025, -$64.8 million for Q2 2025, and $866.6 million during Q1 2025.